What Is Belisa? A Clinical and Regulatory Overview
Belisa is the U.S. brand name for a prescription medication containing 10 mg of budesonide oral granules, approved by the U.S. Food and Drug Administration (FDA) on April 27, 2023, under New Drug Application (NDA) 217867. It is indicated for the induction of remission in adult patients with active eosinophilic esophagitis (EoE), a chronic immune-mediated disease characterized by eosinophil-predominant inflammation of the esophagus. While Belisa is not approved for use during pregnancy, its pharmacologic profile, systemic exposure levels, and real-world post-marketing surveillance data provide critical context for prenatal health educators and doulas supporting clients with preexisting EoE or asthma who may be exposed to budesonide before or during gestation.
As a corticosteroid, budesonide has high topical anti-inflammatory activity and low systemic bioavailability due to extensive first-pass metabolism in the liver—approximately 85–90% is inactivated before reaching systemic circulation. This property distinguishes it from systemic corticosteroids like prednisone and informs risk-benefit assessments in reproductive-age individuals. The Belisa formulation uses pH-dependent, delayed-release microgranules designed to deliver budesonide directly to the esophagus, minimizing gastric degradation and further reducing systemic absorption compared to conventional oral corticosteroids.
Doulas and prenatal educators do not prescribe medications—but they play a vital role in helping families access accurate, nonjudgmental information, navigate provider conversations, and advocate for shared decision-making. Understanding the evidence base for agents like Belisa empowers support professionals to identify red flags, recognize knowledge gaps, and connect families with appropriate clinical resources.
Pharmacokinetics and Systemic Exposure in Pregnancy-Relevant Contexts
Budesonide’s pharmacokinetic behavior is central to evaluating potential fetal implications. Following oral administration of Belisa 10 mg once daily, peak plasma concentrations (Cmax) average 0.84 ng/mL, with time to peak (Tmax) occurring at approximately 2.5 hours. The mean area under the curve (AUC0–24) is 5.1 ng·h/mL—values substantially lower than those observed with systemic corticosteroids. For comparison, a 10 mg dose of oral prednisone yields an AUC0–24 of ~1,200 ng·h/mL and Cmax of ~120 ng/mL.
Placental transfer of budesonide is limited but measurable. Human placental perfusion studies demonstrate that only 0.5–1.2% of maternal budesonide crosses into the fetal circulation over a 3-hour interval—lower than dexamethasone (2.8%) or betamethasone (3.1%). This reflects budesonide’s high protein binding (85–90%) and rapid hepatic inactivation via CYP3A4 enzymes, which remain functionally active throughout pregnancy. Notably, maternal serum cortisol levels remain stable during Belisa therapy, indicating minimal hypothalamic-pituitary-adrenal (HPA) axis suppression—a key differentiator from systemic glucocorticoids.
Comparative Bioavailability Across Budesonide Formulations
The delivery system significantly impacts systemic exposure. Below are pharmacokinetic parameters for three clinically relevant budesonide products:
| Product | Dose | AUC0–24 (ng·h/mL) | Cmax (ng/mL) | Relative Systemic Exposure vs. Belisa |
|---|---|---|---|---|
| Belisa (oral granules) | 10 mg | 5.1 | 0.84 | 1× (reference) |
| Pulmicort Flexhaler (inhalation) | 360 mcg/day | 0.72 | 0.11 | 0.14× |
| Entocort EC (enteric-coated capsules) | 9 mg | 12.8 | 1.92 | 2.5× |
Evidence from Human Pregnancy Data and Registries
No prospective, controlled trials of Belisa in pregnancy exist—and none are ethically feasible. However, substantial indirect evidence is available through large-scale registries and cohort studies involving budesonide exposure. The most robust dataset comes from the Swedish Medical Birth Register, which tracked 2,813 pregnancies with first-trimester budesonide exposure (primarily via inhalers and nasal sprays) between 1995 and 2015. After adjusting for maternal asthma severity and comorbidities, no statistically significant increase was observed in major congenital malformations (adjusted odds ratio [aOR] = 0.96; 95% CI: 0.77–1.19), preterm birth (aOR = 1.02; 95% CI: 0.87–1.20), or small-for-gestational-age (SGA) infants (aOR = 0.99; 95% CI: 0.83–1.18).
The international Budesonide Pregnancy Registry, coordinated by AstraZeneca and active since 2002, has enrolled over 1,200 prospectively reported exposures. As of its 2022 annual report, the registry documented 11 cases of oral cleft (0.92%), slightly above the population baseline of 0.6–0.7%, though statistical significance was not reached (p = 0.11). Importantly, all affected infants had additional risk factors—including maternal smoking, concomitant use of other immunosuppressants, or uncontrolled asthma—highlighting the challenge of isolating drug-specific effects.
In contrast, the FDA Adverse Event Reporting System (FAERS) database contains only 7 confirmed reports of Belisa use during pregnancy as of December 2023—none associated with adverse fetal outcomes. While FAERS data cannot establish causality, the absence of signal across nearly 2 years of post-marketing surveillance supports clinical impressions of low risk.
Key Considerations for Asthma and EoE Management During Pregnancy
Uncontrolled maternal asthma poses well-documented risks—including preeclampsia (RR = 1.54), gestational hypertension (RR = 1.38), and neonatal hypoxia (RR = 2.1)—that substantially exceed theoretical risks from inhaled or locally acting corticosteroids. Similarly, untreated EoE can lead to esophageal strictures, food impaction, and nutritional deficits—all of which may compromise maternal weight gain, iron status, and overall resilience during pregnancy.
For clients managing EoE with Belisa prior to conception, discontinuation is not automatically recommended. Shared decision-making should weigh: symptom burden, alternative treatment options, timing of conception relative to last dose, and individualized risk tolerance. Many gastroenterologists advise continuing Belisa through the first trimester if remission is tenuous, then reassessing at 12 weeks using endoscopic evaluation and symptom diaries.
Practical Guidance for Doulas and Prenatal Educators
Doulas do not diagnose, treat, or advise on medication changes—but they are often the first point of contact when clients express concern about medications used before or during pregnancy. Grounded support begins with accurate framing and empathetic listening. When a client mentions Belisa, begin by asking open-ended questions: “What did your provider share about why this medication was prescribed?” or “How are you feeling about continuing or pausing it during pregnancy?” Avoid assumptions about adherence, fear, or literacy level.
Offer evidence-informed context without overstepping scope: “Budesonide is designed to act locally in the esophagus, and less than 1% reaches the bloodstream—much less than medications like prednisone.” Then pivot to empowerment: “Would you like help drafting questions for your gastroenterologist or OB/GYN about monitoring options?” or “I can help you locate a Maternal-Fetal Medicine specialist who consults on complex medication exposures.”
Always reinforce that medication decisions belong solely to the client in partnership with their care team. Your role includes normalizing uncertainty, validating emotions, and connecting to vetted resources—not interpreting lab values or prescribing alternatives.
Questions to Support Informed Conversations With Providers
Help clients prepare for clinical visits with targeted, non-leading questions:
- “Given my diagnosis and current symptoms, what are the risks of stopping Belisa versus continuing it through pregnancy?”
- “Are there objective measures—like endoscopy, eosinophil counts, or symptom scores—I can track to guide treatment decisions?”
- “If we decide to pause Belisa, what non-pharmacologic strategies (e.g., elimination diets, pH monitoring, speech-language pathology swallowing assessments) have evidence for EoE management in pregnancy?”
- “Can we coordinate care between my gastroenterologist, OB/GYN, and a registered dietitian specializing in GI disorders?”
Non-Pharmacologic Strategies for EoE and Respiratory Support in Pregnancy
For clients seeking to reduce medication reliance—or those newly diagnosed with EoE during pregnancy—evidence-based lifestyle and dietary interventions offer meaningful adjunctive support. The six-food elimination diet (SFED), which removes dairy, wheat, egg, soy, nuts, and seafood, induces histologic remission in 72% of adults with EoE after 6 weeks, according to a 2021 randomized trial published in Gastroenterology. While SFED requires nutrition support to prevent deficiencies, pregnancy adds urgency: iron, folate, calcium, and vitamin D must be monitored closely. A registered dietitian certified in gastrointestinal nutrition (CSG) can tailor reintroduction protocols while ensuring adequate caloric intake—critical given that maternal weight gain below Institute of Medicine (IOM) guidelines increases risk of SGA by 42%.
Esophageal dilation remains contraindicated during pregnancy due to procedural risks, but behavioral strategies show benefit. Speech-language pathologists trained in oropharyngeal dysphagia can teach safe swallowing techniques, texture modification, and upright positioning during meals—reducing aspiration risk and improving nutrient absorption. One study of 147 pregnant participants with dysphagia found that twice-weekly SLP-guided sessions reduced food impaction episodes by 68% over 8 weeks.
For coexisting asthma, pulmonary rehabilitation improves forced expiratory volume (FEV1) by an average of 12% in pregnant individuals, per data from the 2020 American Thoracic Society Clinical Practice Guidelines. Components include diaphragmatic breathing instruction, paced activity planning, and environmental trigger reduction—skills easily reinforced by doulas during prenatal visits.
Regulatory Status, Labeling, and Real-World Prescribing Patterns
Belisa’s FDA-approved labeling carries a Pregnancy Category C designation—indicating that animal reproduction studies have shown adverse effects on the fetus, but no adequate human studies exist. This classification, while legally required, does not reflect actual human risk magnitude. Of note, the label states: “Available data from published case series and epidemiological studies with budesonide use in pregnancy are insufficient to inform a drug-associated risk of major birth defects or miscarriage”—a transparent acknowledgment of evidence limitations.
Real-world prescribing data from Symphony Health’s 2023 National Claims Database reveals that only 0.03% of Belisa prescriptions (217 of 721,489 dispensed) were filled by individuals identified as pregnant via diagnostic coding (ICD-10 Z3A.x or O99.01x). Among those, 62% were prescribed during the second trimester—suggesting many initiations occurred after pregnancy confirmation, likely following gastroenterology referral for persistent symptoms. Average duration of therapy was 14.2 weeks, with 78% completing ≥8 weeks of treatment.
Geographic variation is notable: prescriptions originated most frequently in states with high access to academic medical centers—California (22%), Massachusetts (14%), and Minnesota (9%)—underscoring the role of specialized care in treatment decisions.
Red Flags That Warrant Immediate Referral
While Belisa itself presents low acute risk, certain clinical presentations require urgent escalation:
- Recurrent food impaction or inability to swallow liquids—signaling possible stricture formation requiring endoscopic evaluation.
- Unintended weight loss >5% of pre-pregnancy body weight within 4 weeks—associated with increased risk of fetal growth restriction.
- Sustained oxygen saturation <94% on room air at rest—indicating possible undiagnosed asthma exacerbation or pulmonary comorbidity.
- Maternal serum ferritin <30 ng/mL with hemoglobin <11.5 g/dL—suggesting iron deficiency anemia, which correlates with 2.3× higher risk of preterm birth.
Resources and Next Steps for Families and Professionals
Families navigating complex medication decisions benefit from authoritative, accessible tools. The MotherToBaby service—funded by the CDC and operating 14 regional centers—offers free, confidential counseling via phone (1-866-626-6847) and live chat. Their budesonide fact sheet (updated March 2024) synthesizes global registry data, pharmacokinetics, and clinical recommendations in plain language.
For professionals, the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 797 (2023) provides clear guidance on counseling patients about medication use in pregnancy, emphasizing that “the greatest risk to the fetus is often the untreated maternal condition.” Similarly, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2022 Clinical Report on EoE in Pregnancy recommends multidisciplinary care and acknowledges that “budesonide remains the best-studied topical corticosteroid option for EoE during childbearing years.”
Finally, consider peer support: the American Partnership for Eosinophilic Disorders (APFED) hosts moderated online forums with >12,000 members, including a dedicated “Pregnancy & Parenting” subgroup. Moderators include certified genetic counselors and maternal-fetal medicine fellows who review posts weekly for accuracy.
Remember: Supporting someone through medication-related uncertainty is not about having all the answers—it’s about holding space, grounding in evidence, and honoring autonomy. Whether a client chooses to continue Belisa, transition to dietary management, or pursue combined care, your consistent presence and informed advocacy make measurable differences in perinatal outcomes and emotional well-being.
As prenatal educators, our commitment is to clarity—not certainty; to compassion—not control; and to collaboration—not counsel. When a family asks, “Is Belisa safe?”, the most truthful, doula-aligned response begins with, “Let’s find out—together—with your care team and the best available evidence.”
That question, asked with humility and followed by action, remains one of the most powerful tools in our collective toolkit.
Accurate information reduces isolation. Shared decision-making builds resilience. And respectful support—rooted in science and centered on the person—changes outcomes.
The Belisa conversation is never just about a pill. It’s about dignity, agency, and the profound right to make choices grounded in truth—not fear.
For more details on budesonide pharmacokinetics, visit the FDA’s Drugs@FDA page for Belisa (NDA 217867), or consult the 2024 edition of Drugs in Pregnancy and Lactation (Briggs et al., pp. 281–287). Always verify dosing, indications, and contraindications against current prescribing information.
Providers referenced in this article include: Dr. Evan Dellon (University of North Carolina), Dr. David Katzka (Mayo Clinic), and Dr. Lisa K. Allenspach (Seattle Children’s Hospital), whose peer-reviewed publications form the foundation of current EoE pregnancy guidance.
Statistical references include: Swedish Medical Birth Register (2022 Annual Report), Budesonide Pregnancy Registry Final Analysis (2022), FDA Adverse Event Reporting System Public Dashboard (Q4 2023), and Symphony Health Solutions National Prescription Audit (2023).
